Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Essen Biotech
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07066982CT.gov Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd146/her2 car-t cells (this asset) | Essen Biotech | P1/2 | CCC · 48 |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Fludarabine | Essen Biotech | P2 | B |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Teonanacatl | University Health Network, Toronto | P2 | CCC |
| Lifileucel | M.D. Anderson Cancer Center | P2 | CCC |
| Opa-Interacting Protein 4 | Mannkind Corporation | P1 | CC |
| Pembrolizumab | University of Southern California | P1 | CC |
+4 more in the Bone Sarcoma cohort
Other indications for cd146/her2 car-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kaposi'S Sarcoma | — | P1/2 | CCC · 48 |
| Ewing Sarcoma | — | P1/2 | CCC · 48 |
| Soft Tissue Sarcoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd146/her2 car-t cells in Bone Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd146her2-car-t-cells-bone-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →